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Abstract
Background: Most HIV-infected patients receiving virologically suppressive antiretroviral therapy continue to have
abnormal, generalized T cell activation. We explored whether the degree of ongoing cytomegalovirus (CMV), Epstein-Barr
virus (EBV) and Kaposi’s sarcoma herpesvirus (KSHV) replication was associated with higher virus-specific T cell activation
and the failure to achieve normal absolute CD4+ T cell counts in the face of long-term suppressive antiretroviral therapy.
Methodology: Longitudinally collected PBMC and saliva specimens obtained from HIV-infected patients on effective
antiretroviral therapy for at least one year (plasma HIV RNA ,75 copies/mL) were examined using a multiplex CMV, EBV and
KSHV DNA PCR assay. Eleven cases were chosen who had CD8+ T cell CD38+HLA-DR+ expression .10% and plateau
absolute CD4+ T cell counts ,500 cells/mL. Five controls from the same study had CD8+ T cell CD38 expression ,10% and
plateau absolute CD4+ T cell counts .500 cells/mL.
Results and Conclusions: Among all subjects combined, 18% of PMBC samples were positive for CMV DNA, and 27%, 73%
and 24% of saliva samples were positive for CMV, EBV and KSHV DNA, respectively. No significant differences or trends were
observed between cases and controls in proportions of all CMV, EBV or KSHV DNA positive specimens, proportions of
subjects in each group that intermittently or continuously shed CMV, EBV or KSHV DNA in saliva, or the median number of
genome copies of CMV, EBV and KSHV DNA in saliva. Overall, number of genome copies in saliva were lower for KSHV than
for CMV and lower for CMV than for EBV. Although replication of CMV, EBV and KSHV persists in many antiretroviral-
suppressed, HIV-infected patients, we observed no evidence in this pilot case-control study that the magnitude of such
human herpesvirus replication is associated with abnormally increased CD8+ T cell activation and sub-normal plateau
absolute CD4+ T cell counts following virologically suppressive antiretroviral therapy.
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Introduction
Currently available highly active antiretroviral therapy
(HAART) regimens are able to dramatically decrease plasma
HIV RNA levels in the majority of patients with chronic HIV
infection, leading to sustained increases in absolute CD4+ T cell
counts and decreased risk of progression to AIDS and death.
These antiretroviral regimens, however, have limitations in terms
of immunologic efficacy [1]. Most patients whose absolute CD4+
T cell counts are restored to normal range continue to have
elevated levels of T cell activation (as evidenced by the proportion
of T cells expressing CD38 and HLA-DR) and abnormally
elevated levels of B cell activation (as evidenced by elevated serum
IgG concentrations) [2,3]. This persistent immune activation
during therapy likely has clinical significance, as it does in
untreated HIV infection [4,5]. For example, the degree of this
persistent T cell activation is inversely correlated with the extent of
absolute CD4+ T cell count reconstitution [2]. The clinical
sequelae of chronic T and B cell activation in HAART-suppressed
patients remain undefined, but soluble markers of immune
activation have been associated with an increased risk of death
and cardiovascular disease in this setting [6], and chronic
activation has also been associated with an increased risk of
autoimmune disease and cancer in HIV-uninfected populations.
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5277The reasons underlying persistent T and B cell activation, in the
face of effective antiretroviral therapy, are unknown. Potential
causes include 1) persistent HIV replication, at levels below those
detectable using currently available commercial plasma HIV RNA
assays, 2) persistent systemic replication of a co-infecting virus such
as human herpes or hepatitis viruses, 3) persistent microbial
translocation [7], and/or 4) persistent B and T cell dysregulation
that is antigen-independent. Since CMV-specific CD8 T-cell
responses (as measured by the proportion of cells expressing IFNc
after stimulation with pp65 peptides) are higher in HAART-
treated HIV-infected subjects compared to matched uninfected
controls [8] and since CMV-specific CD8+ T cell activation and
differentiation appear elevated during HIV infection [9], we
investigated whether evidence of CMV replication in blood or
saliva might be associated with the degree of peripheral blood
CD8+ T cell activation and absolute CD4+ T cell count recovery
in HIV-infected patients whose plasma HIV RNA had been
suppressed by HAART below the level of detection for at least
one year.
We chose saliva as a compartment to monitor active CMV
replication because of the expectation that this body fluid would
provide a sensitive source of this virus in antiretroviral-suppressed
HIV-infected patients [10,11] as it is in many other settings. We
evaluated CMV DNA levels associated with PBMC instead of
plasma because of the increased sensitivity afforded by this
compartment [12,13].
Finally, given the fact that both EBV or KSHV are also shed in
increased amounts in saliva in HIV-infected patients [9,11] and
that EBV-specific CD8+ T cell activation increases in HIV
infected patients [9,14], we also assessed the DNA levels of these
human herpesviruses in the same saliva samples.
Methods
Subjects
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the University of California San
Francisco. All patients provided written informed consent for the
collection of samples and subsequent analysis.
PMBC and saliva specimens were obtained from a prospective
observational study of HAART (SCOPE). In SCOPE, subjects are
evaluated by medical history and measurement of plasma HIV
viral load and absolute CD4+ T cell count every 4 months. At
each of these visits, samples of blood for plasma and PBMC
separation and of unstimulated whole saliva are obtained and
stored at 280uC. For this study we identified specimens from
SCOPE participants who met the following criteria:
1. On HAART with at least one year of sequential plasma HIV
RNA levels consistently sustained at levels ,75 copies/mL
before the time the first specimens tested were obtained.
2. Paired stored PBMC and saliva specimens were available from
at least 2 separate visits spanning a minimum 6 month period
while the subject remained on HAART with a HIV RNA level
consistently ,75 copies/mL and during which the percentage
of circulating CD8+ T cells co-expressing CD38 and HLA-DR
was measured.
Among the specimens from these participants, we selected
‘‘cases’’ who had high CD8+ T cell activation and low absolute
CD4+ T cell counts at the time specimens tested were obtained,
and were defined as:
N Percentage of circulating CD8+ T cells co-expressing CD38
and HLA-DR was .10%.
N Absolute CD4+ T cell counts were consistently ,500 cells/
mL.
N In addition, since chronic hepatitis C infection has been
reported to cause abnormally increased CD8+ Tc e l l
activation and low absolute CD4+ T cell count in HIV-
coinfected patients [2], only subjects who tested negative
for hepatitis C antibody were included in Group 1.
We also identified a group of controls who had low CD8+ T cell
activation and high absolute CD4+ T cell counts at the time
specimens tested were obtained, defined as:
N Percentage of circulating CD8+ T co-expressing CD38 and
HLA-DR was ,10%
N Absolute CD4+ T cell counts were consistently .500 cells/
mL.
Immunophenotyping of Activated T cells
Freshly drawn EDTA anti-coagulated whole blood was stained,
lysed and fixed as previously described [2]. Activated
(CD38+HLA-DR+) CD8+ T lymphocytes were analyzed by 4-
color flow cytometry on a Beckman Coulter Epics XL flow
cytometer, using FITC-conjugated anti-HLA-DR, PE-conjugated
anti-CD38 (both BD Bioscience), CY5-conjugated anti-CD3, and
ECD-conjugated anti-CD8 (both Beckman Coulter) monoclonal
antibodies. Appropriate isotype controls were used to define the
positive CD38 and HLA-DR populations.
CMV DNA PCR Assay of PBMC
As previously described [15], we amplified viral DNA from
clinical samples with a low background and a sensitivity of 3 to 5
CMV genomes/10
5 cell equivalents. Aliquots of 10
6 freshly
separated PBMC were lysed, boiled for 5 min, cooled on ice,
and stored at 280uC until use. DNA was isolated from samples
using the QIAGEN DNeasy Tissue kit (QIAGEN Inc., Valencia,
CA) according to the manufacturer’s instructions. The initial
amplification of DNA was with primers IEP2AII (59ATG-
GAGTCCTCTGCCAAGAGAAAGATGGAC39) and IEP4BII
(59CAATACACTTCATCTCCTCGAAAGG39), followed by
IEP3B (59TCTGCCAGGACATCTTTCTC39 and IEP3A
(59GTGACCAAGGCCACGACGTT39). For the initial
qualPCR, 5 ml( 1mg; 10
5 cell equivalents) of extracted PBMC
and PMN DNA or 50 ng EMB DNA was added to 45 ml reaction
mixtures containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl,
1.5 mM MgCl2 (Roche Diagnostics Corporation, Indianapolis,
IN), 200 mM of each deoxynucleotide triphosphate (Invitrogen
Corporation), 1 U Taq polymerase (Roche Diagnostics Corpora-
tion), and 1 mM of each primer. For the second qualPCR, 5 ml out
of the first reaction mixture was added to a 45 ml reaction mixture
as used for the initial qualPCR. qualPCR mixtures were layered
with 50 ml of mineral oil and subjected to one cycle of 94uC for
3 min, followed by 30 cycles of 1 min of denaturation at 94uC,
1 min of annealing at 62uC, and 2 min of extension at 72uC, and a
final extension step of 7 min at 72uC. Positive and negative
controls were included in each run, and, after qualPCR, each
sample was electrophoresed through a 2% agarose gel containing
0.2 mg/ml ethidium bromide with appropriate DNA size markers.
Amplicons were visualized on a UV transilluminator and
photographed.
To quantify viral load in the qual-PCR-positive samples, we
used SYBR green detection of real-time PCR products able to
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5 cells.
Real-time PCR was performed in a GeneAmp 5700 Sequence
Detection System (Applied Biosystems, Foster City, CA). Five mlo f
sample was added to 45 ml of reaction mix containing 25 ml SYBR
green PCR Master Mix (Applied Biosystems) and 10 pmol of each
primer. The primers used for the real-time PCR were also located
in the gene encoding the IE1 protein, exon 2 (IE1-2F,
59GGCCGAAGAATCCCTCAAA39; and IE1-2R, 59TCGTTG-
CAATCCTCGGTCA39). Conditions for the real-time PCR were
established empirically and included incubation at 50uC for 2 min
to enable uracil-DNA-glycosylase (in Master Mix) to act on
samples and 94uC for 10 min to activate AmpliTaq Gold
polymerase, followed by 40 cycles of 15 s of denaturation at
94uC and 1 min of annealing and extension at 60uC. A standard
curve of serial dilutions of known amounts of plasmid DNA was
used in each run as an internal control and to determine the copy
number in the samples. In addition, a natural CMV DNA positive
sample was run to assess consistency. The detection limit of this
test was 5 CMV DNA copies/10
5 cells, and positive samples were
quantitated as copies/5 mL of lysed cells. Each run included
positive and negative samples, and specificity of the amplified
products was assessed on each run by dissociation curve analysis to
ensure that all products had an expected, uniform melting
temperature.
Human Herpesvirus DNA PCR Assay of Saliva
DNA was isolated from 250 ml saliva (diluted to 1000 ml with
PBS) using the QIAGEN QIAamp UltraSens Virus Kit (QIAGEN
Inc., Valencia, CA) according to the manufacturer’s instructions.
DNA was eluted in 80 ml 0.16TE pH 7.8 (Fisher Inc.). A single
QPCR reaction contained 14 ml2 6SYBR (Roche Inc.), 1 ml
primer (to yield 167 nM final concentration), 7 ml PCR grade
water and 8 ml sample. Single plex reactions were set up on a
RoboGo (MWG Inc.) pipetting station and analyzed on a MJR
Opticon II machine. Cycle conditions were 56uC: 5 min, 95uC:
3 min, (95uC: 5 sec, 62uC: 30 sec, 406). The primers were for
EBV: EBNA3cF 59- AAGGTGCATTTACCCCACTG, EB-
NA3cR, 59- AGCAGTAGCTTGGGAACACC [16] for KSHV
LANA78f 59- GGAAGAGCCCATAATCTTGC, LANA78r 59-
GCCTCATACGAACTCCAGGT, FOR HCMV GlyBcmvF 59-
AAGTACCCCTATCGCGTGTG, GlyBcmvR 59-ATGATG-
CCCTGATCCAAGTC [17]. A standard curve of serial dilutions
of known amounts of target oligonucleotides was used to
determine the copy number in the samples. Triplicates assays
were performed with each saliva sample, and the median value
was used in data analysis. Samples with melting temperature
,76uC were excluded from the analysis. Samples with ,1.8 log
copies per ml were considered negative.
Statistical Analysis
For analyses including multiple observations per participant, we
evaluated differences in categorical outcomes (i.e., DNA detectable
vs. undetectable) between cases and controls with logistic
regression for clustered data and differences in DNA copy number
between cases and controls with generalized estimating equations.
For analyses comparing DNA copy numbers between groups,
undetectable levels were assigned a value of 1.79 log10 copies/ml
(just below the lower limit of detection of 1.8 log10 copies/ml).
Fisher’s exact tests were used to compare the proportion of cases
and controls with $1, $2, or all samples positive. The Spearman
rank correlation test was used to test the association of subject’s
percent of activated CD8+ T cells with the amount of herpesvirus
DNA in their saliva.
Results
Eleven SCOPE subjects meeting the criteria for inclusion were
sampled as cases in the high CD8 T cell activation/low CD4 count
group. The cases had 2–4 saliva and PMBC specimens assayed
which spanned a 6–12 month period. The cases had a median
(range) absolute CD4+ T cell count of 279 (112–450) cells/mL and
percentage of activated (CD38+HLA-DR+) CD8+ T cells of
17.9% (11–38%) during this study period. Five subjects met the
criteria for inclusion as controls in the lower CD8 T cell
activation/higher CD4 count group, had 4 PMBC and saliva
specimens assayed which spanned a 12 month period, and had a
median (range) absolute CD4+ T cell count of 687 (519–858)
cells/mL and percentage of activated (CD38+HLA-DR+) CD8+ T
cells of 5.4% (4–7.6%) during this study period. Demographics
and characteristics of the subjects studied are summarized in
Table 1. Of note, there was a trend toward longer duration of
sustained undetectable plasma HIV RNA on antiretroviral
therapy in the control group (58 vs. 31 months, p=0.06).
Human Herpesvirus DNA PCR
Table 2 summarizes comparisons of the proportion of all case
and control saliva and PBMC specimens that were positive (above
the cut-off value of 1.8 log/mL of saliva for each of the three
human herpesvirus DNA or $5 CMV DNA copies/10
5 cells in
PBMC), as well as comparisons of the proportion of case and
control subjects who had $1, $2 or all saliva specimens positive.
In addition, salivary herpesvirus DNA levels (log10 copies/mL)
Table 1. Subject Demographics and Characteristics at time of first specimen.
High CD8+/CD38+%- Low CD8+/CD38+%-
Low Abs. CD4+ count High Abs. CD4+ count
N 11 5
Age (median, range years) 49 (42–62) 48 (39–54)
Male:Female 10:1 5:0
White:Black:Hispanic:Asian/Pacific Islander 8:2:1:0 2:1:0:2
Absolute CD4+ T cells/mL (median, range) 279 (112–450) 687 (519–858)
Percent of CD8+ T cells that are CD38+HLA-DR+ (median, range) 17.9 (11–38) 5.4 (4.0–7.6)
Months plasma HIV VL undetectable (median, range) 31 (16–53) 58 (24–74)
doi:10.1371/journal.pone.0005277.t001
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estimating equations.
Among all subjects combined, 18% of PMBC samples were
positive for CMV DNA and 27%, 73% and 24% of saliva samples
were positive for CMV, EBV and KSHV DNA, respectively.
However, all categorical comparisons between the case and
control groups were non-significant with p values .0.5, and all
comparisons of median DNA copy number between cases and
controls were non-significant with p values .0.9.
As there was no consistent difference between the cases and
controls interms of any of the herpesviruses measured, we combined
the groupsto determineifthelevelofCMV,EBVorKSHVDNAin
saliva was associated with the level of CD8+ T cell activation. The
time point of saliva collection temporally closest to that of a CD8+ T
cell CD38/HLA-DR expression measurement was used. We found
nocorrelationbetweenthepercentageofactivatedCD8+Tce ll sa n d
the amount of CMV DNA (r=0.193, p=0.47), EBV DNA
(r=20.254, p=0.34), or KSHVDNA (r=0.259, p=0.33)insaliva.
In general, positive readings tended to occur within subjects,
suggesting that the ‘‘steady-state’’ levels varied by subject. Of note,
all positive PBMC samples had very low copy numbers, ,3 CMV
DNA copies per 5 mL of lysed cells. Also, the number of genome
copies in saliva overall were lower for KSHV than for CMV and
lower for CMV than for EBV.
Discussion
Replication of CMV, EBV and KSHV persists in many
antiretroviral-suppressed, HIV-infected patients to a greater
degree than in HIV-uninfected adults [9]. T cell activation is also
consistently higher in antiretroviral-suppressed patients compared
to HIV negatives, and when present is often associated with
suboptimal gains in absolute CD4+ T cells. To explore the possible
causal role of persistent herpesvirus replication on immune
activation and immune reconstitution during suppressive antiret-
roviral therapy, we selected two distinct groups of patients: those
with relatively normal CD8+ T cell activation/high absolute
CD4+ T cell counts and those with high CD8+ T cell activation/
low absolute CD4+ T cell counts. Using very sensitive measures of
herpesvirus persistence, we found no consistent association
between the level of viral DNA and immune activation. We also
found no evidence suggesting that residual viral replication during
suppressive antiretroviral therapy was causally associated with
either high T cell activation. The proportions of all CMV, EBV or
KSHV DNA positive specimens between the cases and controls
were essentially the same, as were the proportions of subjects in
each group that intermittently or continuously shed CMV, EBV or
KSHV DNA in saliva. In addition, the median number of copies
of CMV, EBV and KSHV DNA longitudinally in cases was
virtually identical to that in controls.
Miller, et al, previously reported results using a similar PCR
assay to detect CMV, EBV and KSHV in similar unstimulated
whole saliva specimens from 58 HIV-infected patients, most of
whom had HIV replication suppressed by antiretroviral therapy
[11]. In that study, 31%, 57% and 90% of saliva samples were
positive for CMV, KSHV and EBV DNA, respectively, compared
to 37%, 26% and 71% in our study. Perhaps, the lower number of
positive KSHV and EBV specimens we observed was a result of
Table 2. Comparison of saliva and PBMC human herpes virus DNA PCR results between groups of HIV-infected, antiretroviral
suppressed patients with high CD8+/CD38+% and low absolute CD4+ T cell counts versus those with low CD8+/CD38+% and high
absolute CD4+ T cell counts.
High CD8+/CD38+%- Low CD8+/CD38+%- P value
Low Abs. CD4+ count High Abs. CD4+ count
CMV DNA PCR
Positive saliva samples 10/35 5/20 0.77
Positive PBMC samples 8/40 3/20 0.61
Pts with $1 positive saliva 5/11 4/5 0.31
Pts with $2 positive saliva 4/11 1/5 1.00
Pts with all positive saliva 0/11 0/5 -
Mean within-subject mean saliva CMV DNA copy number
(log10 copies/mL)
1.89 1.91 0.73
EBV DNA PCR
Positive saliva samples 25/35 15/20 0.83
Pts with $1 positive saliva 10/11 5/5 1.00
Pts with $2 positive saliva 8/11 4/5 1.00
Pts with all positive saliva 5/11 2/5 0.55
Mean within-subject mean saliva EBV DNA copy number
(log10 copies/mL)
3.16 3.38 0.74
KSHV DNA PCR
Positive saliva samples 9/35 4/20 0.61
Pts with $1 positive saliva 7/11 3/5 1.00
Pts with $2 positive saliva 2/11 1/5 1.00
Pts with all positive saliva 0/11 0/5 -
Mean within-subject mean saliva KSHV DNA copy number
(log10 copies/mL)
2.0 2.1 0.55
doi:10.1371/journal.pone.0005277.t002
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completely suppressed below the limit of plasma detectability by
commercial assay for at least one year.
Similar to the results from Miller et al, we noticed that median
CMV levels were lower than median KSHV levels, which in turn
were lower than median EBV levels (Table 2). This suggests that
even though herpesvirus shedding is often considered a categorical
event (i.e., a person either has undetectable viral load or is actively
shedding virus), the amount of virus that can be transmitted orally
by a person experiencing viral reactivation differs considerably for
the different herpesviruses.
This pilot study has several important limitations. First and
foremost, the sample size was small, and thus the potential Type II
error is likely substantial. However, we avoided confounding
factors by requiring prolonged HIV RNA undetectability in
plasma for study eligibility and excluding patients with chronic
HCV infection. Second, we selected our cases and controls based
on more than one factor (i.e., the groups differed based on both
CD8+ T cell activation and absolute CD4+ T cell counts). This
study design would have been particularly problematic had we
observed differences between the two groups. Since it is unlikely
that low absolute CD4+ T cell counts may have blunted the
impact of herpes viruses on immune activation, it is also unlikely
that the negative results observed in this study were due to our
study design. Third, we only measured human herpesvirus
replication in two reservoirs, saliva and PBMC. Assaying
specimens from other reservoirs (e.g., genital secretions, urine,
plasma) may have demonstrated a difference between the two
groups. In addition, the saliva and PBMC specimens we assayed
were obtained infrequently (only once every four months).
Sampling more frequently, for example by daily oral swabs [10],
might reveal differences between these two groups of patients in
the frequency and duration of herpesvirus replication. Since it is
impractical to assay all potential reservoirs of human herpesvirus
daily, an alternative method to determine the role of human
herpesvirus replication in driving abnormal T cell activation in
HIV-infected patients would be to administer therapy with an
agent with broad anti-herpesvirus activity, such as valganciclovir,
and then measure the effect on T cell activation and absolute
CD4+ T cell count in a randomized, controlled manner. We are
currently performing such a trial.
Given the strong association between inflammation/immune
activation and disease outcomes in treated HIV disease, defining
the mechanisms associated with HIV-associated inflammation is of
high importance. Our preliminary data do not provide strong
evidence for a role of persistent high level herpesvirus replication.
Other possible mechanisms includes the following:
1. Persistent microbial translocation. It is now well-appreciated
that HIV causes irreversible damage to the gut mucosal
integrity early in the course of disease, leading to translocation
of gut microbial products into the system circulation [18].
Circulating lipopolysaccharide and bacterial DNA have each
been reported to correlate with measures of T cell activation in
HIV-infected patients [7,19].
2. Residual HIV viremia. Another factor leading to persistent
abnormal immune activation in antiretroviral-suppressed
patients could be persistent low level replication of HIV.
Several studies have reported that by using an ultra-
ultrasensitive HIV RNA PCR assay, low levels of plasma
HIV viremia (below the detectability of currently available
commercial HIV RNA assays) can be detected in the majority
of HIV-infected patients successfully treated with antiretroviral
therapy [20–24]. Results of these studies indicate that the level
of this residual viremia remains stable for at least up to seven
years [23,24]. Of note, the duration of suppressive antiretro-
viral therapy in the controls we studied tended to be longer
than in the cases, which could be consistent with the controls
having a lower level of HIV replication than the cases.
3. Persistant immune dysregulation. Finally, the damage to the
immune system done by uncontrolled HIV replication before
antiretroviral therapy is initiated, for example in altering T cell
diversity in adults with limited thymic reserve for repopulating
diverse naı ¨ve T cells [25] or reducing the number of regulatory
T cells [26–29], could result in persistent T cell dysregulation
that is antigen-independent.
In summary, future studies to examine the effect of suppressing
CMV, EBV and KSHV with drugs such as valganciclovir [10]
may better clarify the role of persistent human herpesvirus
replication in driving abnormal T cell activation and resultant
incomplete immune reconstitution in patients with HIV infection.
Furthermore, observational studies that measure HIV RNA by
ultra-ultrasensitive assays [20], circulating lipopolysaccharide and/
or bacterial DNA, and measurements of regulatory T cells or T
cell superfamily representation (a method to characterize T cell
diversity) and correlate these parameters with measurements of T
cell activation and absolute CD4+ T cell counts in cohorts of long-
term, antiretroviral suppressed patients could help elucidate the
etiologic contributions of microbial translocation, low level HIV
replication, and persistent T cell dysregulation to this pathologic
process.
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